Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 196Triple Negative Breast Neoplasms 26Neoplasm Metastasis 18Breast Neoplasms, Male 13Ovarian Neoplasms 9Inflammatory Breast Neoplasms 9Pancreatic Neoplasms 8Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Multiple Myeloma 2Lymphedema 2Hematologic Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Uterine Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

exemestane 1Paclitaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
First Line Metastatic Breast Cancer × Bevacizumab × Breast × Clear all
NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

ARCAGY/ GINECO GROUP

Phase 3 Terminated
117 enrolled
Breast

First Line Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡